Gossamer Bio Q3 net loss per share narrows 57% year over year to $7.36

• Gossamer Bio’s third-quarter 2026 net loss narrowed year over year to $48.07 million.
• Revenue more than doubled year over year to $38.43 million, primarily due to revenue recognized upon termination of the Chiesi collaboration.
• Research and development expenses fell 59% year over year to $18.83 million, primarily driven by lower seralutinib clinical-trial costs.
• The first seralutinib NDA was submitted in September 2026 for pulmonary arterial hypertension; a potential commercial launch is planned for 2027.
• FDA acceptance of the NDA in 2026 could unlock approximately $125 million in additional private-placement proceeds, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261110967921) on November 10, 2026, and is solely responsible for the information contained therein.